StockNews.AISignal intelligence
GH Research PLC · NASDAQ · Healthcare
Browse public GHRS signals with their source context and measured market impact. Open any signal for its permanent analysis page.
GHRS received positive catalysts from robust TRD data for GH001, a cleared path toward Phase 3 after the FDA IND hold was lifted. UK Phase 1 pharmacology results informed dosing for the pivotal program, while BPL-003's shorter duration may offer a competitive edge. The stock moved higher on the news, underscoring near-term upside if Phase 3 execution remains on track.
View signal analysisGH Research reported a first-quarter loss of 31 cents per share, exceeding losses projected by analysts. Despite the setback, the company affirmed its commitment to the GH001 Phase 3 program, leading analysts to adjust their price targets for the stock, which fell 3.4% post-announcement.
View signal analysisFDA lifted the clinical hold on GH001, a key milestone for GHRS. GH001 shows significant improvement in treatment-resistant depression patients. Global pivotal program for GH001 expected to launch in 2026. GHRS shares gained 34.52% after FDA announcement. Competitors are advancing their treatments in a growing market.
View signal analysisNeedham initiated coverage on GHRS, stating impressive Phase 2 efficacy. FDA hold on GH001 remains; one topic requires more data. GH001 achieved a 73% remission rate in Phase 2b at six months. Needham sets a $19 price target for GHRS, rating it as Buy. Potential sales for GH001 could reach $1.9 billion by 2035.
View signal analysis